<DOC>
	<DOCNO>NCT02214693</DOCNO>
	<brief_summary>This clinical study investigate pharmacokinetics/pharmacodynamics tolerability DA-1229 ( Evogliptin ) tabletin renal impaired patient .</brief_summary>
	<brief_title>PK//PD/Tolerability Study DA-1229 ( Evogliptin ) Renal Impaired Patients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Age 20 70 Weights 50 90kg ( Female : 40 90kg ) Volunteer totally understand progress clinical trial , make decision free , signed consent form follow progress Stable result estimate GFR 4 month recently Volunteer past present history disease follow . ( liver include hepatitis virus carrier , kidney , Neurology , immunology , pulmonary , endocrine , hematooncology , cardiology , mental disorder ) Volunteer drug ( DPP4 inhibitor ) hypersensitivity reaction Volunteer already participate trial 2 month Volunteer whole blood donation 2 month , component blood donation 1 month transfusion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>patient</keyword>
</DOC>